|Bid||0.0000 x 1000|
|Ask||0.0000 x 3000|
|Day's Range||3.9900 - 4.3000|
|52 Week Range||1.1300 - 8.3900|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||2.74|
|Earnings Date||Mar 10, 2020 - Mar 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
THE WOODLANDS, Texas, Jan. 20, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be.
THE WOODLANDS, Texas, Jan. 06, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at.
Shares of Lexicon Pharmaceuticals Inc. are down 5% in premarket trading on Friday after the biopharmaceutical company said that its experimental Type 2 diabetes treatment met its primary and secondary endpoints in a late-stage clinical trial. The therapy, Zynquista, is already approved in Europe. Earlier this month, Lexicon said that the Food and Drug Administration had denied a company appeal that the regulator reconsider approving Zynquista as a Type 1 diabetes treatment. The company said Dec. 2 it plans to appeal the decision again. Lexicon's stock is down 33% year-to-date, compared to the S&P 500 , which is up 27%.
Lexicon Pharmaceuticals, Inc. (LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. Sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo at Week 26 in patients with type 2 diabetes who have inadequate glycemic control on a dipeptidyl peptidase 4 inhibitor (DPP4i) with or without metformin.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Lonnel Coats has been the CEO of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) since 2014. This analysis aims first to...
Lexicon Pharmaceuticals, Inc. (LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain. "We are pleased that the initial clinical data for LX9211 in the multiple ascending dose study supports continued advancement of the drug," said Praveen Tyle, Ph.D., executive vice president of research and development at Lexicon. The randomized, double-blind, placebo-controlled, multiple ascending dose Phase 1 study was performed to evaluate the safety, tolerability and pharmacokinetics of orally administered LX9211 in healthy volunteers.
THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2 clinical study of telotristat ethyl in patients with biliary tract cancer. Telotristat ethyl is a novel, oral tryptophan hydroxylase (TPH) inhibitor approved as XERMELO® for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy alone.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2.
Lexicon Pharmaceuticals Inc. shares slid 31% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has denied its appeal of a decision relating to a diabetes treatment. The Woodlands, Texas-based company said the FDA denied its appeal of a Complete Response Letter relating to its new drug application for sotagliflozin in type 1 diabetes. The company said it would appeal the decision and will hold a conference call at 8.00 a.m. Eastern. The FDA issued the Complete Response Letter, a ruling that means it cannot accept a NDA in its present form, back in February. Lexicon shares have fallen 47% in 2019, while the S&P 500 has gained 25%.
Lexicon Pharmaceuticals, Inc. (LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response Letter in relation to the New Drug Application for sotagliflozin (ZynquistaTM) in type 1 diabetes. Lexicon management will hold a live conference call today, December 2, 2019, at 8:00 am EST / 7:00 am CST to discuss today’s announcement.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
THE WOODLANDS, Texas, Nov. 07, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.
Lexicon Pharmaceuticals, Inc. (LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Ines Ferre discuss the markets at the opening bell on The First Trade.